{
    "clinical_study": {
        "@rank": "8393", 
        "arm_group": {
            "arm_group_label": "Prevenar (13v)"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate post marketing use and safety of Prevnar ( 13v)\n      in infants vaccinated for the first time at the age of 2 months, inclusive, to 7 months,\n      exclusive."
        }, 
        "brief_title": "Prevenar (13v) Infant Drug Use Investigation", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Infants", 
        "detailed_description": {
            "textblock": "The investigation will be conducted using the continuous investigation method, with which a\n      satisfying registration conditions will be continuously registered until the number of\n      contracted cases is reached."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Vaccinees who meet all of the following conditions at the time of the first\n             vaccination among infants who use Prevenar 13 in accordance with the indication, and\n             dosage and administration of the vaccine will be included in the investigation:\n\n          -  Infants aged 2 months, inclusive, to 7 months, exclusive\n\n          -  Infants with no history of administration of pneumococcal vaccines including Prevenar\n             13\n\n          -  Infants expected to receive 4 vaccinations\n\n        Exclusion Criteria:\n\n          -  Vaccines must not be performed if the vaccinee corresponds to any of the following:\n\n          -  Persons in whom a past history of anaphylaxis due to an ingredient of Prevenar 13 or\n             diphtheria toxoid is evident\n\n          -  Persons with evident pyrexia\n\n          -  Persons who evidently have serious acute diseases\n\n          -  Besides the persons listed above, persons who are in a status inappropriate for\n             immunization"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "7 Months", 
            "minimum_age": "2 Months", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Vaccinees who meet all of the following conditions at the time of the first vaccination\n        among infants who use Prevenar 13 in accordance with the indication, and dosage and\n        administration of the vaccine will be included in the investigation."
            }
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02119104", 
            "org_study_id": "B1851122"
        }, 
        "intervention": {
            "arm_group_label": "Prevenar (13v)", 
            "description": "Prevenar (13v)", 
            "intervention_name": "Prevenar (13v)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 17, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1851122&StudyName=Prevenar%20%2813v%29%20Infant%20Drug%20Use%20Investigation"
        }, 
        "number_of_groups": "1", 
        "official_title": "Prevenar (13v) Infant Drug Use Investigation (Regulatory Post Marketing Commitment Plan) - Investigation in Infants Starting Vaccination at the Age of 2 Months, Inclusive, to 7 Months, Exclusive", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of the participants with adverse reaction", 
            "safety_issue": "Yes", 
            "time_frame": "52 weeks (MAX)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02119104"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}